BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Karlsen TH, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E, Pryke R, Hutchinson SJ, Sangro B, Martin NK, Cecchini M, Dirac MA, Belloni A, Serra-Burriel M, Ponsioen CY, Sheena B, Lerouge A, Devaux M, Scott N, Hellard M, Verkade HJ, Sturm E, Marchesini G, Yki-Järvinen H, Byrne CD, Targher G, Tur-Sinai A, Barrett D, Ninburg M, Reic T, Taylor A, Rhodes T, Treloar C, Petersen C, Schramm C, Flisiak R, Simonova MY, Pares A, Johnson P, Cucchetti A, Graupera I, Lionis C, Pose E, Fabrellas N, Ma AT, Mendive JM, Mazzaferro V, Rutter H, Cortez-Pinto H, Kelly D, Burton R, Lazarus JV, Ginès P, Buti M, Newsome PN, Burra P, Manns MP. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet 2022;399:61-116. [PMID: 34863359 DOI: 10.1016/S0140-6736(21)01701-3] [Cited by in Crossref: 53] [Cited by in F6Publishing: 66] [Article Influence: 53.0] [Reference Citation Analysis]
Number Citing Articles
1 Fromenty B, Roden M. Mitochondrial alterations in fatty liver diseases. J Hepatol 2023;78:415-29. [PMID: 36209983 DOI: 10.1016/j.jhep.2022.09.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Nevens F, Trauner M, Manns MP. Primary biliary cholangitis as a roadmap for the development of novel treatments for cholestatic liver diseases(†). J Hepatol 2023;78:430-41. [PMID: 36272496 DOI: 10.1016/j.jhep.2022.10.007] [Reference Citation Analysis]
3 Targher G, Mantovani A, Byrne CD. Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease. Lancet Gastroenterol Hepatol 2023;8:179-91. [PMID: 36620987 DOI: 10.1016/S2468-1253(22)00338-7] [Reference Citation Analysis]
4 van Kleef LA, Sonneveld MJ, Kavousi M, Ikram MA, de Man RA, de Knegt RJ. Fatty liver disease is not associated with increased mortality in the elderly: A prospective cohort study. Hepatology 2023;77:585-93. [PMID: 35753042 DOI: 10.1002/hep.32635] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
5 Verma S, Verne J, Ufere NN. Palliative care in advanced liver disease: time for action. Lancet Gastroenterol Hepatol 2023;8:106-8. [PMID: 36620976 DOI: 10.1016/S2468-1253(22)00382-X] [Reference Citation Analysis]
6 Hagström H, Simon TG, Söderling J, Ludvigsson JF. Autopsy histology data suggest cirrhosis is frequently under-reported on death certificates. Hepatol Commun 2023;7:e0015. [PMID: 36691952 DOI: 10.1097/HC9.0000000000000015] [Reference Citation Analysis]
7 Serper M, Kaplan DE, Taddei TH, Tapper EB, Cohen JB, Mahmud N. Nonselective beta blockers, hepatic decompensation, and mortality in cirrhosis: A national cohort study. Hepatology 2023;77:489-500. [PMID: 35984731 DOI: 10.1002/hep.32737] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Vaz J, Strömberg U, Midlöv P, Eriksson B, Buchebner D, Hagström H. Unrecognized liver cirrhosis is common and associated with worse survival in hepatocellular carcinoma: A nationwide cohort study of 3473 patients. J Intern Med 2023;293:184-99. [PMID: 36166276 DOI: 10.1111/joim.13570] [Reference Citation Analysis]
9 Raptis DD, Mantzoros CS, Polyzos SA. Fibroblast Growth Factor-21 as a Potential Therapeutic Target of Nonalcoholic Fatty Liver Disease. Ther Clin Risk Manag 2023;19:77-96. [PMID: 36713291 DOI: 10.2147/TCRM.S352008] [Reference Citation Analysis]
10 Brahmania M, Biondi MJ, Joshi S, Lee E, Jung H, Kehar M. Priority actions for elevating liver health in Canada: A call to action. Canadian Liver Journal 2023. [DOI: 10.3138/canlivj-2022-0041] [Reference Citation Analysis]
11 Zhang J, Lai Z, Ding R, Zhou J, Yuan Z, Li D, Qin X, Zhou J, Li Z. Diagnostic potential of site-specific serotransferrin N-glycosylation in discriminating different liver diseases. Clin Chim Acta 2023;539:175-83. [PMID: 36543268 DOI: 10.1016/j.cca.2022.12.015] [Reference Citation Analysis]
12 Ortner J, Van Ewijk RJ, Velthuis L, Labenz C, Arslanow A, Wörns MA, Reichert MC, Farin-Glattacker E, Fichtner UA, Stelzer D, Galle PR, Lammert F. Costs of a structured early detection program for advanced liver fibrosis and cirrhosis: insights on the "plus" of Check-up 35. Z Gastroenterol 2023. [PMID: 36623821 DOI: 10.1055/a-1989-1971] [Reference Citation Analysis]
13 MacGilchrist A. Scotland's alcohol crisis: A clinician's perspective on a public health emergency. J R Coll Physicians Edinb 2023;:14782715221146607. [PMID: 36606672 DOI: 10.1177/14782715221146607] [Reference Citation Analysis]
14 Cucchetti A, Casadei-Gardini A. Liver resection for HCC in patients with metabolic syndrome: questions answered, questions raised. Hepatology 2023. [PMID: 36645223 DOI: 10.1097/HEP.0000000000000034] [Reference Citation Analysis]
15 Goodheart RH, Ayonrinde OT. Depiction of alcohol-related liver disease in the EASL International Liver Congress. J Hepatol 2023;78:e36-8. [PMID: 35988684 DOI: 10.1016/j.jhep.2022.08.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Fu CE, Ng CH, Yong JN, Chan KE, Xiao J, Nah B, Bong SHS, Win KM, Bwa AH, Lim WH, Tan DJH, Zeng RW, Chew N, Teng MLP, Siddiqui MS, Oben JA, Sanyal AJ, Wong VW, Noureddin M, Muthiah M. A Meta-analysis on Associated Risk of Mortality in Nonalcoholic Fatty Liver Disease. Endocr Pract 2023;29:33-9. [PMID: 36273685 DOI: 10.1016/j.eprac.2022.10.007] [Reference Citation Analysis]
17 Wells G, Spiers J, Williams FR, Li W, Tavabie OD, Brennan PN. An overview of the challenges and key initiatives in hepatology practice in the UK in 2022: a cautionary tale, but reasons for optimism - British Association for the Study of the Liver (BASL) Annual Meeting 2022 Conference Report. Clin Med (Lond) 2023;23:73-5. [PMID: 36697015 DOI: 10.7861/clinmed.2022-0443] [Reference Citation Analysis]
18 Lønsmann I, Steen Pedersen J, Krag A, Hansen T, Karsdal M, Julie Leeming D, Juul Nielsen M, Bendtsen F. Biomarkers reflecting pericellular fibrosis improve together with liver histology after bariatric surgery in early non-alcoholic fatty liver disease. Clin Biochem 2022;113:29-35. [PMID: 36574896 DOI: 10.1016/j.clinbiochem.2022.12.012] [Reference Citation Analysis]
19 Shea S, Lionis C, Atkinson L, Kite C, Lagojda L, Chaggar SS, Kyrou I, Randeva HS. Support Needs and Coping Strategies in Non-Alcoholic Fatty Liver Disease (NAFLD): A Multidisciplinary Approach to Potential Unmet Challenges beyond Pharmacological Treatment. Livers 2022;3:1-20. [DOI: 10.3390/livers3010001] [Reference Citation Analysis]
20 Ginès P, Buti M, Lazarus JV, Sangro B. Liver diseases: a sanitary and social challenge for Europe in the XXI Century. Results of EASL-Lancet Comission. Med Clin (Barc) 2022;159:598-603. [PMID: 36041936 DOI: 10.1016/j.medcli.2022.07.010] [Reference Citation Analysis]
21 Monteiro CA, Astrup A. Does the concept of "ultra-processed foods" help inform dietary guidelines, beyond conventional classification systems? YES. Am J Clin Nutr 2022;116:1476-81. [PMID: 35670127 DOI: 10.1093/ajcn/nqac122] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 16.0] [Reference Citation Analysis]
22 Wang J, Qin X, Kong B, Ren H. Celery‐derived scaffolds with liver lobule‐mimicking structures for tissue engineering transplantation. Smart Medicine 2022. [DOI: 10.1002/smmd.20220002] [Reference Citation Analysis]
23 Canillas L, Soriano-Varela A, Rodríguez-Campello A, Giralt-Steinhauer E, Cuadrado-Godia E, Broquetas T. High prevalence of non-alcoholic fatty liver disease in patients with a first episode of acute ischemic stroke. Impact on disability and death. Front Endocrinol (Lausanne) 2022;13:1003878. [PMID: 36589812 DOI: 10.3389/fendo.2022.1003878] [Reference Citation Analysis]
24 Park J, MacLean MT, Lucas AM, Torigian DA, Schneider CV, Cherlin T, Xiao B, Miller JE, Bradford Y, Judy RL, Verma A, Damrauer SM, Ritchie MD, Witschey WR, Rader DJ; Regeneron Genetics Center. Exome-wide association analysis of CT imaging-derived hepatic fat in a medical biobank. Cell Rep Med 2022;3:100855. [PMID: 36513072 DOI: 10.1016/j.xcrm.2022.100855] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Ventura-Cots M, Bataller R, Lazarus JV, Benach J, Pericàs JM. Applying an equity lens to liver health and research in Europe. J Hepatol 2022;77:1699-710. [PMID: 35985542 DOI: 10.1016/j.jhep.2022.07.021] [Reference Citation Analysis]
26 Shiha G, Korenjak M, Casanovas T, Mooney V, Sigurðardóttir S, Koulla Y, Soliman R. MAFLD 2022: An ELPA/ALPA/EASO-ECPO joint statement on disease stigma. J Hepatol 2022;77:1717-9. [PMID: 36055431 DOI: 10.1016/j.jhep.2022.08.027] [Reference Citation Analysis]
27 Lindvig KP, Wernberg CW, Kjaergaard M, Thorhauge KH, Alnor AB, Thiele M, Krag A. Only one-third of referrals for fatty liver disease are on time: real-world study reveals opportunities to avoid unnecessary and delayed referrals. Scand J Gastroenterol 2022;57:1478-85. [PMID: 35793386 DOI: 10.1080/00365521.2022.2094725] [Reference Citation Analysis]
28 Kaur S, Kidambi S, Ortega-Ribera M, Thuy LTT, Nieto N, Cogger VC, Xie WF, Tacke F, Gracia-Sancho J. In Vitro Models for the Study of Liver Biology and Diseases: Advances and Limitations. Cell Mol Gastroenterol Hepatol 2022;15:559-71. [PMID: 36442812 DOI: 10.1016/j.jcmgh.2022.11.008] [Reference Citation Analysis]
29 Hundt MA, Tien C, Kahn JA. Addressing sex-based disparities in liver transplantation. Current Opinion in Organ Transplantation 2022;Publish Ahead of Print. [DOI: 10.1097/mot.0000000000001040] [Reference Citation Analysis]
30 Laleman W, Praktiknjo M, Lauridsen MM, Bonne L, Vanderschueren E, Verslype C, Krag A, Trebicka J, Maleux G. Closing spontaneous portosystemic shunts in cirrhosis: Does it make sense? Does it work? What does it take? Metab Brain Dis 2022. [DOI: 10.1007/s11011-022-01121-2] [Reference Citation Analysis]
31 van der Meer D, Gurholt TP, Sønderby IE, Shadrin AA, Hindley G, Rahman Z, de Lange AG, Frei O, Leinhard OD, Linge J, Simon R, Beck D, Westlye LT, Halvorsen S, Dale AM, Karlsen TH, Kaufmann T, Andreassen OA. The link between liver fat and cardiometabolic diseases is highlighted by genome-wide association study of MRI-derived measures of body composition. Commun Biol 2022;5:1271. [PMID: 36402844 DOI: 10.1038/s42003-022-04237-4] [Reference Citation Analysis]
32 Fortea JI, Crespo J, Puente Á. Cirrhosis, a Global and Challenging Disease. JCM 2022;11:6512. [DOI: 10.3390/jcm11216512] [Reference Citation Analysis]
33 Tilg H, Adolph TE, Trauner M. Gut-liver axis: Pathophysiological concepts and clinical implications. Cell Metab 2022;34:1700-18. [PMID: 36208625 DOI: 10.1016/j.cmet.2022.09.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
34 Ginès P, Buti M, Lazarus JV, Sangro B. Liver diseases: A sanitary and social challenge for Europe in the XXI Century. Results of EASL-Lancet Comission. Medicina Clínica (English Edition) 2022. [DOI: 10.1016/j.medcle.2022.07.018] [Reference Citation Analysis]
35 Rolland B, Lions C, Di Beo V, Carrieri P, Authier N, Barré T, Delorme J, Mathurin P, Bailly F, Protopopescu C, Marcellin F. Adherence to opioid agonist therapy predicts uptake of direct-acting antivirals in people who use drugs: results from the French national healthcare database (the ANRS FANTASIO study). Harm Reduct J 2022;19:119. [PMID: 36303159 DOI: 10.1186/s12954-022-00702-9] [Reference Citation Analysis]
36 Pryke R, Guha IN. Time to focus on chronic liver diseases in the community: A review of primary care hepatology tools, pathways of care and reimbursement mechanisms. J Hepatol 2022:S0168-8278(22)03146-4. [PMID: 36283499 DOI: 10.1016/j.jhep.2022.10.010] [Reference Citation Analysis]
37 Tejada-Pérez JJ, Herrera-Burgos MR, Parrón-Carreño T, Alarcón-Rodríguez R. Biohazard Accidents, Harmful Elements to the Wellness of Healthcare Workers, and Their Risk Factors. Int J Environ Res Public Health 2022;19. [PMID: 36293794 DOI: 10.3390/ijerph192013214] [Reference Citation Analysis]
38 Marjot T, Eberhardt CS, Boettler T, Belli LS, Berenguer M, Buti M, Jalan R, Mondelli MU, Moreau R, Shouval D, Berg T, Cornberg M. Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper. J Hepatol 2022;77:1161-97. [PMID: 35868584 DOI: 10.1016/j.jhep.2022.07.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
39 Invernizzi F, Cilla M. Liver Transplantation in Patients with Alcohol-Associated Liver Disease: Current Strategies and Future Perspectives. Controversies in Liver Transplantation - Recent Challenges and Future Perspectives [Working Title] 2022. [DOI: 10.5772/intechopen.104799] [Reference Citation Analysis]
40 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL Clinical Practice Guidelines on sclerosing cholangitis. J Hepatol 2022;77:761-806. [PMID: 35738507 DOI: 10.1016/j.jhep.2022.05.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
41 Allaire M, Bruix J, Korenjak M, Manes S, Maravic Z, Reeves H, Salem R, Sangro B, Sherman M. What to do about Hepatocellular Carcinoma: Recommendations for Health Authorities: An International Liver Cancer Association Advocacy Document. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100578] [Reference Citation Analysis]
42 Jepsen P, Reeves H. Signed, SEALed, detected I'm your patient with advanced fibrosis or cirrhosis! J Hepatol 2022;77:591-2. [PMID: 35738506 DOI: 10.1016/j.jhep.2022.06.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Labenz C, Arslanow A, Nguyen-Tat M, Nagel M, Wörns MA, Reichert MC, Heil FJ, Mainz D, Zimper G, Römer B, Binder H, Farin-Glattacker E, Fichtner U, Graf E, Stelzer D, Van Ewijk R, Ortner J, Velthuis L, Lammert F, Galle PR. Structured Early detection of Asymptomatic Liver Cirrhosis: Results of the population-based liver screening program SEAL. J Hepatol 2022;77:695-701. [PMID: 35472313 DOI: 10.1016/j.jhep.2022.04.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
44 Kardashian A, Serper M, Terrault N, Nephew LD. Health disparities in chronic liver disease. Hepatology 2022. [PMID: 35993341 DOI: 10.1002/hep.32743] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Ripoll C, Bleidorn J, Zipprich A. SEAL: Why was this approach not effective? J Hepatol 2022:S0168-8278(22)02997-X. [PMID: 35985544 DOI: 10.1016/j.jhep.2022.07.031] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Kalpadakis S, Sifaki-pistolla D, Symvoulakis EK, Kelefiotis-stratidakis P, Vamvakas L, Mavroudis D, Lionis C. Reporting Liver Cancer Trends in the Island of Crete, Greece: Results from a Geo-Epidemiological Study. IJERPH 2022;19:10166. [DOI: 10.3390/ijerph191610166] [Reference Citation Analysis]
47 Innes H, Morling JR, Buch S, Hamill V, Stickel F, Guha IN. Performance of routine risk scores for predicting cirrhosis-related morbidity in the community. J Hepatol 2022;77:365-76. [PMID: 35271950 DOI: 10.1016/j.jhep.2022.02.022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
48 Schomerus G, Leonhard A, Manthey J, Morris J, Neufeld M, Kilian C, Speerforck S, Winkler P, Corrigan PW. The stigma of alcohol-related liver disease and its impact on healthcare. J Hepatol 2022;77:516-24. [PMID: 35526787 DOI: 10.1016/j.jhep.2022.04.026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
49 Craciun A, Cortez-pinto H. Alarming increase of NASH as cause of liver cancer. Cell Reports Medicine 2022;3:100723. [DOI: 10.1016/j.xcrm.2022.100723] [Reference Citation Analysis]
50 Costa M, Barré T, Antwerpes S, Coste M, Bureau M, Ramier C, Maradan G, Riccobono-soulier O, Vassas-goyard S, Casanova D, Carrieri P. A Community-Based Therapeutic Education Programme for People with Alcohol Use Disorder in France: A Qualitative Study (ETHER). IJERPH 2022;19:9228. [DOI: 10.3390/ijerph19159228] [Reference Citation Analysis]
51 Björnsson ES, Stephens C, Atallah E, Robles-Diaz M, Alvarez-Alvarez I, Gerbes A, Weber S, Stirnimann G, Kullak-Ublick G, Cortez-Pinto H, Grove JI, Lucena MI, Andrade RJ, Aithal GP. A new framework for advancing in drug-induced liver injury research. The Prospective European DILI Registry. Liver Int 2023;43:115-26. [PMID: 35899490 DOI: 10.1111/liv.15378] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
52 van Kleef LA, Sonneveld MJ, de Knegt RJ. Reply. Hepatology 2022. [PMID: 35862439 DOI: 10.1002/hep.32679] [Reference Citation Analysis]
53 Graupera I, Thiele M, Ma AT, Serra-Burriel M, Pich J, Fabrellas N, Caballeria L, de Knegt RJ, Grgurevic I, Reichert M, Roulot D, Schattenberg JM, Pericas JM, Angeli P, Tsochatzis EA, Guha IN, Garcia-Retortillo M, Morillas RM, Hernández R, Hoyo J, Fuentes M, Madir A, Juanola A, Soria A, Juan M, Carol M, Diaz A, Detlefsen S, Toran P, Fournier C, Llorca A, Newsome PN, Manns M, de Koning HJ, Serra-Burriel F, Cucchietti F, Arslanow A, Korenjak M, van Kleef L, Falcó JL, Kamath PS, Karlsen TH, Castera L, Lammert F, Krag A, Ginès P; LiverScreen Consortium investigators. LiverScreen project: study protocol for screening for liver fibrosis in the general population in European countries. BMC Public Health 2022;22:1385. [PMID: 35854275 DOI: 10.1186/s12889-022-13724-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Geng A, Flint E, Bernsmeier C. Plasticity of monocytes and macrophages in cirrhosis of the liver. Front Netw Physiol 2022;2. [DOI: 10.3389/fnetp.2022.937739] [Reference Citation Analysis]
55 Mantovani A, Zusi C, Csermely A, Salvagno GL, Colecchia A, Lippi G, Maffeis C, Targher G. Association between lower plasma adiponectin levels and higher liver stiffness in type 2 diabetic individuals with nonalcoholic fatty liver disease: an observational cross-sectional study. Hormones (Athens) 2022. [PMID: 35831700 DOI: 10.1007/s42000-022-00387-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Tergast TL, Blach S, Tacke F, Berg T, Cornberg M, Kautz A, Manns M, Razavi H, Sarrazin C, Serfert Y, van Thiel I, Zeuzem S, Wedemeyer H. Updated epidemiology of hepatitis C virus infections and implications for hepatitis C virus elimination in Germany. J Viral Hepat 2022;29:536-42. [PMID: 35357770 DOI: 10.1111/jvh.13680] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Chapiro J. Translating artificial intelligence from code to bedside: The road towards AI-driven predictive biomarkers for immunotherapy of hepatocellular carcinoma. J Hepatol 2022;77:6-8. [PMID: 35417743 DOI: 10.1016/j.jhep.2022.03.035] [Reference Citation Analysis]
58 Kalo E, Sheriff N, Isaac M, Baig A, Read S, Ahlenstiel G. A Call for Implementation of an Evidence-Based, Quality Improvement, Decompensated Cirrhosis Discharge Care Bundle in Australia. Livers 2022;2:97-104. [DOI: 10.3390/livers2020007] [Reference Citation Analysis]
59 Niu L, Thiele M, Geyer PE, Rasmussen DN, Webel HE, Santos A, Gupta R, Meier F, Strauss M, Kjaergaard M, Lindvig K, Jacobsen S, Rasmussen S, Hansen T, Krag A, Mann M. Noninvasive proteomic biomarkers for alcohol-related liver disease. Nat Med 2022. [PMID: 35654907 DOI: 10.1038/s41591-022-01850-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
60 Kimura K, Kanto T, Shimoda S, Harada K, Kimura M, Nishikawa K, Imamura J, Ogawa E, Saio M, Ikura Y, Okusaka T, Inoue K, Ishikawa T, Ieiri I, Kishimoto J, Todaka K, Kamisawa T. Safety, tolerability, and anti-fibrotic efficacy of the CBP/β-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study. EBioMedicine 2022;80:104069. [PMID: 35605429 DOI: 10.1016/j.ebiom.2022.104069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
61 Moore JB. COVID-19, childhood obesity, and NAFLD: colliding pandemics. The Lancet Gastroenterology & Hepatology 2022;7:499-501. [DOI: 10.1016/s2468-1253(22)00100-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Wallace SJ, Tacke F, Schwabe RF, Henderson NC. Understanding the cellular interactome of non-alcoholic fatty liver disease. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100524] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
63 Galatou E, Mourelatou E, Hatziantoniou S, Vizirianakis IS. Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs. Antioxidants 2022;11:1060. [DOI: 10.3390/antiox11061060] [Reference Citation Analysis]
64 Guillot A, Tacke F. Location, location, location - spatial insight into hepatic macrophage populations. Nat Rev Gastroenterol Hepatol 2022;19:281-2. [PMID: 35288701 DOI: 10.1038/s41575-022-00600-2] [Reference Citation Analysis]
65 Donnelly MC, Stableforth W, Krag A, Reuben A. The negative bidirectional interaction between climate change and the prevalence and care of liver disease: A joint BSG, BASL, EASL, and AASLD commentary. J Hepatol 2022;76:995-1000. [PMID: 35331574 DOI: 10.1016/j.jhep.2022.02.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
66 Donnelly MC, Stableforth W, Krag A, Reuben A. The Negative Bidirectional Interaction Between Climate Change and the Prevalence and Care of Liver Disease: A Joint BSG, BASL, EASL, and AASLD Commentary. Gastroenterology 2022;162:1561-7. [PMID: 35331440 DOI: 10.1053/j.gastro.2022.02.020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
67 Gabbia D, Roverso M, Sarcognato S, Zanotto I, Ferri N, Russo FP, Guido M, Bogialli S, De Martin S. The Metabolic Activation of Sofosbuvir Is Impaired in an Experimental Model of NAFLD. Biology 2022;11:693. [DOI: 10.3390/biology11050693] [Reference Citation Analysis]
68 Burra P, Ferrarese A. Transplanting severely obese cirrhotic patients: Heavy clouds still on the horizon. United European Gastroenterol J 2022. [PMID: 35474616 DOI: 10.1002/ueg2.12234] [Reference Citation Analysis]
69 Carol M, Pérez-Guasch M, Solà E, Cervera M, Martínez S, Juanola A, Ma AT, Avitabile E, Napoleone L, Pose E, Graupera I, Honrubia M, Korenjak M, Torres F, Ginès P, Fabrellas N; LiverHope Consortium Investigators. Stigmatization is common in patients with non-alcoholic fatty liver disease and correlates with quality of life. PLoS One 2022;17:e0265153. [PMID: 35385510 DOI: 10.1371/journal.pone.0265153] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
70 Barré T, Di Marzo V, Marcellin F, Burra P, Carrieri P. Expanding Research on Cannabis-Based Medicines for Liver Steatosis: A Low-Risk High-Reward Way Out of the Present Deadlock? Cannabis Cannabinoid Res 2022. [PMID: 35420457 DOI: 10.1089/can.2022.0014] [Reference Citation Analysis]
71 Byrne CD, Newsome PN, Noureddin M. Why are there no strategies for NAFLD? J Hepatol 2022;76:763-4. [PMID: 34933023 DOI: 10.1016/j.jhep.2021.12.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
72 Fromme M, Strnad P. Pathophysiology of Chronic Liver Disease Development. Int J Mol Sci 2022;23:3385. [PMID: 35328801 DOI: 10.3390/ijms23063385] [Reference Citation Analysis]
73 Andersson ER. Outside influence: The extrahepatic duct as a source for bile duct regeneration. Hepatology 2022;75:505-7. [PMID: 35006621 DOI: 10.1002/hep.32334] [Reference Citation Analysis]
74 van der Meer D, Gurholt TP, Sønderby IE, Shadrin AA, Hindley G, Rahman Z, de Lange AG, Frei O, Leinhard OD, Linge J, Simon R, Westlye LT, Halvorsen S, Dale AM, Karlsen TH, Kaufmann T, Andreassen OA. The role of liver fat in cardiometabolic diseases is highlighted by genome-wide association study of MRI-derived measures of body composition.. [DOI: 10.1101/2022.02.24.481887] [Reference Citation Analysis]
75 Lazarus JV, Mark HE, Rinella ME, Colombo M. Editorial: global liver fat accumulation and global health-towards a sustainable development goal. Authors' reply. Aliment Pharmacol Ther 2022;55:489-90. [PMID: 35092059 DOI: 10.1111/apt.16768] [Reference Citation Analysis]
76 Macpherson I, Abeysekera KWM, Harris R, Mansour D, McPherson S, Rowe I, Rosenberg W, Dillon JF, Yeoman A; Specialist Interest Group in the Early Detection of Liver Disease Members. Identification of liver disease: why and how. Frontline Gastroenterol 2022;13:367-73. [PMID: 36051960 DOI: 10.1136/flgastro-2021-101833] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
77 Antwerpes S, Costa M, Coste M, Bureau M, Maradan G, Cutarella C, Leloutre J, Riccobono-Soulier O, Hedoire S, Frot E, Vernier F, Vassas-Goyard S, Barré T, Casanova D, Carrieri P. Evaluation of a novel therapeutic education programme for people with alcohol use disorder in France: a mixed-methods intervention study protocol (ETHER). Harm Reduct J 2022;19:2. [PMID: 35012570 DOI: 10.1186/s12954-021-00587-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
78 Pabjan P, Brzdęk M, Chrapek M, Dziedzic K, Dobrowolska K, Paluch K, Garbat A, Błoniarczyk P, Reczko K, Stępień P, Zarębska-Michaluk D. Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals? Viruses 2022;14:96. [PMID: 35062302 DOI: 10.3390/v14010096] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
79 Grabherr F, Grander C, Effenberger M, Schwärzler J, Tilg H. MAFLD: what 2 years of the redefinition of fatty liver disease has taught us. Therapeutic Advances in Endocrinology 2022;13:204201882211391. [DOI: 10.1177/20420188221139101] [Reference Citation Analysis]